( en | de | ru )

 

Disambiguation of "Kahlert, Yvonne"

Author of the publication

copydeleteadd this publication to your clipboard
Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease.

, , , , , , , , , , and . Cancer Lett, 250 (2): 250--267 (June 2007)
DOI: 10.1016/j.canlet.2006.10.016

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

Josef Kahlert

Annamarie Kahlert

Holger Kahlert

Margit Kahlert

Steffen Kahlert

 

Other publications of authors with the same name

Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers., , , , , , , , , and 27 other author(s). Clin Cancer Res, 21 (8): 1904-1915 (April 2015)The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models., , , , , , , , , and 193 other author(s). Nat Biotechnol, 28 (8): 827--838 (August 2010)Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers, , , , , , , , , and 27 other author(s). Clinical Cancer Research, (September 2014)Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome., , , , , , , , , and . Clin Cancer Res, 12 (17): 5118--5128 (September 2006)Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification., , , , , , , , , and 4 other author(s). J Clin Oncol, 24 (31): 5070--5078 (November 2006)Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease., , , , , , , , , and 1 other author(s). Cancer Lett, 250 (2): 250--267 (June 2007)High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma., , , , , , , , , and 8 other author(s). Clin Cancer Res, 17 (15): 5082--5092 (August 2011)Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR., , , , , , , , and . Clin Cancer Res, 14 (20): 6590--6601 (October 2008)